Nicole LaBrosse - Feb 16, 2023 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role
SVP, CHIEF FINANCIAL OFFICER
Signature
/s/ James R. Oehler, Attorney-in-Fact
Stock symbol
HALO
Transactions as of
Feb 16, 2023
Transactions value $
-$124,382
Form type
4
Date filed
2/21/2023, 06:00 PM
Previous filing
Feb 17, 2023
Next filing
Feb 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HALO Common Stock Options Exercise $0 +5.09K +78.41% $0.00 11.6K Feb 16, 2023 Direct
transaction HALO Common Stock Sale -$124K -2.53K -21.78% $49.26 9.07K Feb 16, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HALO Restricted Stock Units Options Exercise $0 -5.09K -25% $0.00 15.3K Feb 16, 2023 Common Stock 5.09K $0.00 Direct F2
transaction HALO Option to Purchase Common Stock Award $0 +61.1K $0.00 61.1K Feb 16, 2023 Common Stock 61.1K $49.26 Direct F3
transaction HALO Restricted Stock Units Award $0 +21.3K $0.00 21.3K Feb 16, 2023 Common Stock 21.3K $0.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported disposition of 2,525 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
F2 This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.
F3 This option vests one-fourth on such date and then 1/48th monthly thereafter.
F4 This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.